March 28th 2024
Five of the company’s vaccines are currently in Phase III.
Streamlining for Safety: Navigating Changes and Trends in the Pharmaceutical Supply Chain Post-DSCSA
March 1st 2024With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.
Generic Drug Shortages Prompt Federal Agencies to Probe Practices of GPOs, Drug Wholesalers
February 15th 2024The Federal Trade Commission and the Department of Health and Human Services are seeking public input to evaluate how policymakers can address chronic drug shortages and promote a resilient supply chain.
Strategizing High-Wire, Multi-Indication Launches
February 14th 2024Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Sanofi, AstraZeneca Launch Program to Mitigate Future RSV Vaccine Shortages
February 2nd 2024New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.
In New Year, Resolve to Solve Drug Supply Chain Security Act Compliance
January 31st 2024Under the DSCSA law, wholesale distributors, re-packagers, dispensers, and other third-party logistics providers must implement interoperable and electronic tracing of prescription products at the package level.